Winslow Asset Management Inc. Reduces Holdings in Johnson & Johnson (NYSE:JNJ)

Winslow Asset Management Inc. lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.2% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 30,024 shares of the company’s stock after selling 671 shares during the period. Winslow Asset Management Inc.’s holdings in Johnson & Johnson were worth $4,979,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. grew its position in shares of Johnson & Johnson by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 232,792,559 shares of the company’s stock worth $33,666,460,000 after buying an additional 1,772,706 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Johnson & Johnson by 2.8% during the fourth quarter. Geode Capital Management LLC now owns 57,667,920 shares of the company’s stock worth $8,321,881,000 after buying an additional 1,561,036 shares in the last quarter. Northern Trust Corp grew its position in shares of Johnson & Johnson by 12.3% during the fourth quarter. Northern Trust Corp now owns 30,813,175 shares of the company’s stock worth $4,456,201,000 after buying an additional 3,363,235 shares in the last quarter. Norges Bank acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth approximately $4,390,037,000. Finally, Wellington Management Group LLP grew its position in shares of Johnson & Johnson by 1.8% during the fourth quarter. Wellington Management Group LLP now owns 24,356,572 shares of the company’s stock worth $3,522,447,000 after buying an additional 431,205 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $155.38 on Wednesday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The company has a market cap of $373.86 billion, a price-to-earnings ratio of 17.28, a price-to-earnings-growth ratio of 2.14 and a beta of 0.41. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. The firm has a fifty day moving average of $153.80 and a 200-day moving average of $154.64.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The company had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of recent analyst reports. Raymond James Financial decreased their price target on shares of Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a research report on Monday, April 14th. Benchmark raised shares of Johnson & Johnson to a “strong-buy” rating in a report on Thursday, April 24th. Guggenheim reaffirmed a “neutral” rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Leerink Partners downgraded shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $169.00 to $153.00 in a report on Tuesday, May 13th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a report on Thursday, June 5th. Eleven equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $171.00.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.